Quantitative projection of human brain penetration of the H₃ antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy

References

• Ashworth S, Rabiner EA, Gunn RN, et al. (2010). Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med 51:1021–9
   PubMed Web of Science ®Google Scholar
• Bostrom E, Simonsson US, Hammarlund-Udenaes M. (2006). In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 34:1624–31
   PubMed Web of Science ®Google Scholar
• Bouras TIM, Gatzonis SS, Georgakoulias N, et al. (2011). Neuro-inflammatory sequelae of minimal trauma in the non-traumatized human brain. J Neurotrauma. [Epub ahead of print]
   Google Scholar
• Chaurasia CS, Muller M, Bashaw ED, et al. (2007). AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24:1014–25
   PubMed Web of Science ®Google Scholar
• Clinckers R, Smolders I, Vermoesen K, et al. (2009). Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations. Expert Opin Drug Metab Toxicol 5:1267–77
   PubMed Web of Science ®Google Scholar
• Cunningham VJ, Rabiner EA, Slifstein M, et al. (2010). Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30:46–50
   PubMed Web of Science ®Google Scholar
• de Lange EC, Danhof M. (2002). Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41:691–703
   PubMed Web of Science ®Google Scholar
• Doran AC, Osgood SM, Mancuso JY, Shaffer CL. (2012). An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos 40:2162–73
   PubMed Web of Science ®Google Scholar
• Gallezot JD, Zheng MQ, Lim K, et al. (2014). Parametric imaging and test-retest variability of 11C-(+)-PHNO binding to D2/D3 dopamine receptors in humans on the high-resolution research tomograph PET scanner. J Nucl Med 55:960–6
   PubMed Web of Science ®Google Scholar
• Gallezot JD, Planeta B, Nabulsi N, et al. (2016). Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. J Cereb Blood Flow Metab. Doi:10.1177/0271678X16650697
   PubMedGoogle Scholar
• Grunder G, Fellows C, Janouschek H, et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165:988–95
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M. (2000). The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev 45:283–94
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. (2008). On the rate and extent of drug delivery to the brain. Pharm Res 25:1737–50
   PubMed Web of Science ®Google Scholar
• Hargreaves RJ, Rabiner EA. (2014). Translational PET imaging research. Neurobiol Dis 61:32–8
   PubMed Web of Science ®Google Scholar
• Institute of Laboratory Animal Resources. (1996). Guide for the care and use of laboratory animals. 7th ed. Washington, DC: Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council
   Google Scholar
• Kalvass JC, Maurer TS, Pollack GM. (2007). Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660–6
   PubMed Web of Science ®Google Scholar
• Liu X, Smith BJ, Chen C, et al. (2006). Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443–7
   PubMed Web of Science ®Google Scholar
• Liu X, Van Natta K, Yeo H, et al. (2009). Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787–93
   PubMed Web of Science ®Google Scholar
• Morgan P, Van Der Graaf PH, Arrowsmith J, et al. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17:419–24
   PubMed Web of Science ®Google Scholar
• Ooie T, Terasaki T, Suzuki H, Sugiyama Y. (1997). Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Dispos 25:784–9
   PubMed Web of Science ®Google Scholar
• Rollema H, Alexander GM, Grothusen JR, et al. (1989). Comparison of the effects of intracerebrally administered MPP+ (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat and monkey striatum. Neurosci Lett 106:275–81
   PubMed Web of Science ®Google Scholar
• Salinas C, Weinzimmer D, Searle G, et al. (2010). Measuring in vivo receptor affinity: comparison of methods using the H3 ligand [11C]GSK189254 in baboon. J Nucl Med Meeting Abstracts 51:213
   Google Scholar
• Saunders NR. (1986). Development of human blood-CSF-brain barrier. Develop Med Child Neurol 28:261–3
   PubMed Web of Science ®Google Scholar
• Shaffer CL, Osgood SM, Mancuso JY, Doran AC. (2014). Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. J Pharm Sci 103:1557–62
   PubMed Web of Science ®Google Scholar
• Shen DD, Artru AA, Adkison KK. (2004). Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825–57
   PubMed Web of Science ®Google Scholar
• Tillement JP, Urien S, Chaumet-Riffaud P, et al. (1988). Blood binding and tissue uptake of drugs. Recent advances and perspectives. Fundam Clin Pharmacol 2:223–38
   PubMed Web of Science ®Google Scholar
• van Beijsterveldt LE, Geerts RJ, Leysen JE, et al. (1994). Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114:53–62
   PubMed Web of Science ®Google Scholar
• Wager TT, Pettersen BA, Schmidt AW, et al. (2011). Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarbox amide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyc lobutanecarboxamide (PF-03654764). J Med Chem 54:7602–20
   PubMed Web of Science ®Google Scholar
• Yao BB, Sharma R, Cassar S, et al. (2003). Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur J Pharmacol 482:49–60
   PubMed Web of Science ®Google Scholar